Eugenia supra-axillaris Essential Oil and Its Nanoemulsion: Chemical Characterization, In Vivo Anti-Inflammatory, Analgesic, and Antipyretic Activities

Table 2

Effect of oral administration of ESA-EO and ESA-EO-NE on GSH, MDA, and NO.

Group	GSH (µmol/mg tissue)	MDA (nmol/mg tissue)	NO (Mmol/L)
Negative control	1.183 ± 0.05^bcd	0.329 ± 0.03^bcd	14.37 ± 0.46^bcd
Carrageenan	0.449 ± 0.02^ac	1.95 ± 0.06^acd	59.60 ± 01.34^acd
Diclofenac (30 mg/kg)	0.852 ± 0.04^ab	0.538 ± 0.02^abd	25.13 ± 01.08^ab
Celecoxib (50 mg/kg)	0.538 ± 0.04^a	0.840 ± 0.02^abc	29.75 ± 0.17^ab
ESA-EO (50 mg/kg)	0.513 ± 0.02^ac	0.851 ± 0.04^abc	41.67 ± 0.87^abcd
ESA-EO (100 mg/kg)	0.703 ± 0.05^ac	0.478 ± 0.02^abd	32.70 ± 0.46^ab
ESA-EO-NE (50 mg/kg)	0.785 ± 0.04^ab	0.417 ± 0.02^bcd	25.28 ± 0.58^ab
ESA-EO-NE (100 mg/kg)	0.88 ± 0.05^b	0.371 ± 0.01^bcd	16.77 ± 0.22^bd

Data are expressed as mean ± SE where n = 6. Statistics were carried out by one-way ANOVA and confirmed by Tukey’s multiple comparison test. was assumed to denote statistical significance. ^aStatistically significant from the control negative group. ^bStatistically significant from the carrageenan group. ^cStatistically significant from the diclofenac group. ^dStatistically significant from the celecoxib group.